Aberrant activation of epithelial-mesenchymal transition (EMT) in carcinoma cells contributes to increased migration and invasion, metastasis, drug resistance, and tumor-initiating capacity. EMT is not always a binary process, rather cells may exhibit a hybrid epithelial/mesenchymal (E/M) phenotype. ZEB1 -a key transcription factor driving EMT -can both induce and maintain a mesenchymal phenotype. Recent studies have identified two novel autocrine feedback loops utilizing ESRP1, HAS2, and CD44 that maintain high levels of ZEB1. However, how the crosstalk between these feedback loops alters the dynamics of epithelial-hybrid-mesenchymal transition remains elusive. Here, using an integrated theoretical-experimental framework, we identify that these feedback loops can enable cells to stably maintain a hybrid E/M phenotype. Moreover, computational analysis identifies the regulation of ESRP1 as a crucial node, a prediction that is validated by two complementary experiments showing that (a) overexpression of ESRP1 reverts EMT in MCF10A cells treated with TGFβ for 21 days, and (b) knockdown of ESRP1 in stable hybrid E/M H1975 cells drives EMT. Finally, in multiple breast cancer datasets, high levels of ESRP1, ESRP1/HAS2, and ESRP1/ZEB1 correlates with poor prognosis, supporting the relevance of ZEB1/ESRP1 and ZEB1/HAS2 axes in tumor progression. Together, our results unravel how these interconnected feedback loops act in concert to regulate ZEB1 levels and to drive the dynamics of epithelial-hybrid-mesenchymal transition.
Introduction
Epithelial-Mesenchymal Transition (EMT) and its reverse Mesenchymal-Epithelial Transition (MET) are embryonic programs that get aberrantly activated during tumor progression [1] , and regulate metastasis [2] . EMT is characterized by affecting one or more of these traitsdecreased cell-cell adhesion, rearranged cytoskeleton, disrupted apico-basal polarity, and increased migration and invasion [3] . Furthermore, EMT contributes to drug resistance [4] , evasion of the immune system [5] , and tumor-initiating properties [6, 7] . EMT can be induced by multiple micro-environmental conditions such as matrix stiffness [8, 9] and hypoxia [10] that can activate one or more of EMT-driving transcription factors such as ZEB (ZEB1/2), Snail (SNAI1/2), and Twist [11] . ZEB1 -a key driver of EMT -can confer tumor-initiating (stemness) and chemoresistance properties to cancer cells [12, 13] , and its expression correlates with poor prognosis [14] . ZEB1 mainly acts as a transcriptional repressor for genes involved in cell-cell adhesion and cell polarity [11] , and for microRNAs that promote an epithelial phenotype such as the miR-200 family [15, 16] . The miR-200 family also represses ZEB1 translation, thereby forming a mutually inhibitory feedback loop [17, 18] , referred to as the 'motor of cellular plasticity' [19] . Higher levels of ZEB1 is key to maintaining a mesenchymal phenotype [20] .
Recent computational models have suggested that the miR-200/ZEB1 feedback loop can not only allow cells to attain an epithelial (high miR-200, low ZEB) and a mesenchymal (low miR-200, high ZEB) phenotype [21, 22] , but also a hybrid epithelial/mesenchymal (E/M) state -(medium miR-200, medium ZEB) [23] [24] [25] . Indeed, active nuclear ZEB1 was observed in H1975 lung cancer cells [26] that maintain a stable hybrid E/M state at a single-cell level over many passages [27] . These earlier models presumed a self-activation of ZEB1 [23] [24] [25] , based on ZEB1-mediated stabilization of SMAD complexes [23] ( Figure 1A ). More recently, exact molecular mechanisms mediating a ZEB1 self-activation were elucidated [28, 29] .
Particularly, ZEB1 can self-activate through two interconnected feedback loops. First, ZEB1 represses epithelial splicing regulatory protein 1 (ESRP1) [29] that controls alternative splicing of the cell surface receptor CD44 which is differentially regulated during EMT [30] . Decreased ESRP1 leads to enhanced levels of CD44s (CD44 standard; devoid of all variable exons) isoform, and depleted levels of variable-exon containing CD44v (CD44 variant) isoforms. Overexpression of CD44s, in turn, activates ZEB1, whereas increase in CD44v isoforms inhibits ZEB1 [29] ( Figure 1B ). Second, ZEB1 activates hyaluronic acid synthase 2 (HAS2) that synthesizes hyaluronic acid (HA) -a key proteoglycan in the extracellular matrix that, in turn, elevates the levels of ZEB1 [28] ( Figure 1B ). These two feedback loops are connected due to interactions of HA with its receptor CD44. CD44s was reported to be essential for the effect of HA on ZEB1, suggesting that HA binding to its receptor CD44s affects EMT [28] . CD44s-HA interactions have been proposed to protect cells undergoing EMT against anoikis [31] , a trait commonly associated with EMT [32] , thereby reinforcing the role of CD44s-HA interactions in this process. CD44s overexpression together with excess of HA leads to even higher levels of ZEB1 as compared to CD44s overexpression alone [28] . Hence, CD44s may be able to activate ZEB1 through both HA-dependent and HA-independent pathways. However, how these complex interconnections among these feedback loops regulating ZEB1 drive the emergent dynamics of epithelial-hybrid-mesenchymal transitions remains elusive.
Here, using an integrated theoretical-experimental approach, we elucidated the dynamics of the interconnected feedback loops among ZEB1, ESRP1, HAS2, and CD44 in mediating epithelialhybrid-mesenchymal transitions. First, we constructed a mathematical model denoting the known interactions among these players. The model predicted that these feedback loops can enable for the existence of a stable hybrid E/M phenotype, besides epithelial and mesenchymal phenotypes. Sensitivity analyses on model parameters identify ESRP1 as a key mediator of EMT and MET. Consistently, overexpression of ESRP1 in MCF10A cells treated with TGFβ reversed EMT, while knockdown of ESRP1 in stable hybrid E/M cells -H1975 -drove EMT. Finally, higher levels of ESRP1, ESRP1/HAS2, and ESRP1/ZEB1 correlates with poor patient survival, indicating the functional relevance of these feedback loops during tumor progression.
Results

Mathematical modeling suggests how the miR-200/ZEB1/ESRP1/HAS2/CD44 circuit drives the dynamics of epithelial-hybrid-mesenchymal transition
As a first step towards elucidating the dynamics of epithelial-hybrid-mesenchymal transition as driven by ZEB1/ESRP1/HAS2/CD44 feedback loops, we construct a mathematical model representing the experimentally known regulatory interactions among these players (SI section 1). Next, we plot the levels of ZEB1 as a function of an EMT-inducing signal (here, represented by SNAIL), as predicted by the model. We also compared the dynamics of these transitions as mediated by the miR-200/ZEB1/ESRP1/HAS2/CD44 circuit, with the control case, i.e. when ZEB1 self-activation is not included through these detailed pathways (miR-200/ZEB1 circuit), but instead as in earlier modeling attempts [23] [24] [25] .
The response of the different circuits -miR-200/ZEB1 (hereafter referred to as the 'simplified circuit') and miR-200/ZEB1/ESRP1/HAS2/CD44 (hereafter referred to as the 'extended circuit') -to varying levels of SNAIL (mimicking an induction of EMT) is presented as bifurcation diagrams of ZEB1 mRNA levels ( Figure 1C , D). Lower levels of ZEB1 mRNA (<150 molecules) denote an epithelial (E) phenotype, higher values (> 600 molecules) represent a mesenchymal (M) phenotype, and intermediate values (~200-500 molecules) denote a hybrid E/M phenotype (solid blue lines in Figure 1C , D).
The dynamics of these two circuits look remarkably similar. For low SNAIL levels, cells maintain an E phenotype. Increase in SNAIL levels drive cells toward a hybrid E/M phenotype, and a further increase induces a complete EMT, causing cells to attain an M state (black dotted upward arrows in Figure 1C , D). Moreover, for certain SNAIL levels, cells can exhibit more than one phenotype and thus can spontaneously interconvert among one another, for instance, among E and M states in the {E, M} phase (green shaded region in Figure 1C Moreover, in pan-cancer cell line cohorts NCI-60 and CCLE (Cancer Cell Line Encyclopedia), ZEB1 positively correlates with HAS2, and negatively correlates with ESRP1 [26, 28, 29] . This correlation is also observed in lung, breast, and pancreatic tumors [28, 29] , suggesting that these interconnected feedback loops may regulate EMT across cancer types. This idea is further strengthened by a positive correlation between HAS2 and CD44s in breast cancer [33] .
Figure 1. Dynamics of EMT regulatory circuit. A) Simplified EMT regulatory circuit -mutually inhibitory feedback loop between ZEB1 and miR-200, driven by SNAIL. In this earlier modeling attempt, selfactivation of ZEB1 is considered to be direct, to incorporate the stabilization of SMADs by ZEB1. B) Extended EMT regulatory circuit with explicit mechanistic details of ZEB1 self-activation, as identified in recent studies. Solid black lines show transcriptional regulation, dotted black lines show microRNAmediated regulation, and green arrows indicate regulation whose modes are either non-transcriptional or yet have to be identified. C) Bifurcation diagram of the miR-200/ZEB1 (simplified) circuit shown in A), driven by SNAIL. Solid blue curves show stable states (cellular phenotypes), red dotted curves show unstable states. Low levels of ZEB1 denote an epithelial (E) phenotype, high levels of ZEB1 denote a mesenchymal (M) phenotype, and intermediate levels of ZEB1 denote a hybrid E/M phenotype, as shown by cartoons drawn alongside. Different colored regions show different phases -cyan region depicts {E} phase, green region depicts {E, M} phase, brown region depicts {E, E/M, M} phase, pink region depicts {E/M, M} phase, and yellow region depicts {M} phase. D) Bifurcation diagram for the extended, i.e. miR-200/ZEB1/ESRP1/HAS2/CD44 circuit as shown in B).
Sensitivity analysis identifies ESRP1 as a key mediator of epithelial-hybrid-mesenchymal transitions
To evaluate the robustness of the model predictions mentioned above, we performed a sensitivity analysis to parameter perturbation. Our sensitivity analysis for the simplified circuit (i.e. miR-200/ZEB1 circuit without HAS2, CD44, and ESRP1) identified ZEB1 self-activation as a crucial link. Modulating the strength of self-activation significantly affected the range of SNAIL levels for which cells could acquire a stable hybrid E/M phenotype [25] , consistent with observations for such feedback loops enabling three states [34, 35] .
To further assess which link(s) in the extended circuit (miR-200/ZEB1/ESRP1/HAS2/CD44) impact the stability of hybrid E/M phenotype the most, we varied every parameter in the model for this circuit by +/-10%, one at a time, and calculated its effect on the range of SNAIL levels for which cells can acquire a hybrid E/M phenotype (highlighted by black rectangle in Figure  2A ). While the model is largely robust to parameter variation, in a few cases, we noticed a relatively larger change in the region corresponding to a stable hybrid E/M phenotype (highlighted by arrows in Figure 2B ). Particularly, when the strength of inhibition of ESRP1 by ZEB1 is increased, the range of SNAIL levels for the existence of hybrid E/M decreased (Table  S1 ). Conversely, this range increased when the inhibition of ESRP1 by ZEB1 was decreased, or when the biosynthesis rates of ZEB1 were altered (Section S1). These results are in conceptual agreement with the sensitivity analysis for the simplified circuit [25] . Thus, the strength of ZEB1-ESRP1 interaction is likely to play a key role in controlling the stability of a hybrid E/M phenotype, and the dynamics of EMT and MET. Figure 1D , highlighting the region for the existence of a hybrid E/M phenotype, either alone or in combination with other phenotypes. B) Sensitivity analysis for miR-200/ZEB1/ESRP1/HAS2/ CD44 circuit ( Figure 1B) , where the change in the width of the area highlighted in A) is plotted for +/-10% of every parameter, one at a time. Parameters are grouped based on their role in the circuit; green dotted lines denote different groups as mentioned below each group. Red dotted lines marks over +/-20% change in the width of the area highlighted in A). The model predictions are most sensitive to parameters that modulate the strength of ZEB1-ESRP1 link (marked by arrows) C) Solutions from an ensemble of 10,000*3 (n=3) mathematical models, each with a distinct set of parameters, for two conditions -with the ZEB1-ESRP1 link intact (control), and with ZEB1-ESRP1 node deleted (ZEB1-ESRP1 KD). ** p <0.01. For solutions for every set of 10,000 models, frequency of attaining E, M, or hybrid E/M state is plotted. Both plots (above, below) compare the frequency of attaining E, M, and hybrid E/M states in 10,000 control cases vs. 10,000 ZEB1-ESRP1 KD cases.
Figure 2. Sensitivity analysis identifies ZEB1-ESRP1 link as a key regulator for EMT. A) Bifurcation diagram shown in
To further characterize the role of inhibition of ESRP1 by ZEB1 in mediating EMT/MET, we applied our recently developed computational method -Random Circuit Perturbation (RACIPE), [36] -to the miR-200/ZEB/ESRP1/CD44 circuit. For a given circuit topology, RACIPE generates an ensemble of mathematical models and identifies robust gene expression patterns and phenotypes that can be expected from that topology. Here, we used RACIPE to generate 10000 models for the circuit with an intact ZEB1-ESRP1 link (control case) and without this link (ZEB1-ESRP1 KD). Comparing the solutions of this ensemble of models from these both scenarios, attenuated inhibition of ESRP1 by ZEB1, i.e. effectively higher ESRP1 levels, led to decreased propensity to attain a mesenchymal phenotype and an increased propensity to adopt a hybrid E/M state, suggesting that ESRP1 overexpression may halt or reverse EMT ( Figure 2C , S1).
Next, to experimentally test this prediction from our mathematical model, we treated MCF10A cells with TGFβ for 21 days, and then overexpressed ESRP1. Cells treated with TGFβ for 21 days underwent canonical morphological and biochemical changes associated with EMT such as spindle-shaped morphology and increased levels of ZEB1 (MCF10A-TGFβ-Ctrl) [28] . Upon overexpression of ESRP1 (MCF10A-TGFβ-ESRP1), these cells regained a cobblestone-shaped morphology and lost ZEB1 largely ( Figure 3A, B) . Thus, overexpression of EMT can revert EMT progression, an observation consistent with previous reports in using a tamoxifen-dependent activation of Twist-ER in mammary epithelial HMLE cells [30] .
Figure 3. Overexpression of ESRP1 inhibits EMT in MCF10A cells. A) Bright-field microscopy images for MCF10A cells, transfected with a control vector (right) or an ESRP1 overexpression construct (left)after treatment with TGFβ for 21 days. B) Western blot analysis showing changes in ESRP1 and ZEB1 levels in cells presented in A).
ESRP1 knockdown destabilizes a hybrid epithelial/mesenchymal (E/M) phenotype
Next, we investigated how knockdown of ESRP1 can affect EMT. Our previous work has identified several 'phenotypic stability factors' (PSFs) such as OVOL2 and GRHL2 that can stabilize a hybrid E/M phenotype. They form a mutually inhibitory loop with ZEB1 [27] , and their knockdown destabilizes a hybrid E/M phenotype both in vitro [27, 37] and in vivo [38] . Because ESRP1 also forms an effective mutually inhibitory loop with ZEB1 by regulating the alternative splicing of CD44, we hypothesized that knockdown of ESRP1 may destabilize a hybrid E/M phenotype similarly.
To investigate this hypothesis, we knocked down ESRP1 via two independent siRNAs in H1975 -lung cancer cells that display a hybrid E/M phenotype stably over multiple passages in vitro under normal culturing conditions [27] . Untreated H1975 cells co-expressed E-cadherin (CDH1) and Vimentin (VIM) and showed nuclear localization of ZEB1 at a single-cell level (Figure 4 , left 2 columns). Conversely, knockdown of ESRP1 substantially reduced E-cadherin and increased nuclear levels of ZEB1 ( Figure 4A , right 2 columns), thus indicative of a transition towards a more mesenchymal phenotype. These observations go along with decrease of E-cadherin and increase of Vimentin and ZEB1 on protein and RNA levels ( Figure 4B, S2) and an increased spindle-shape morphology ( Figure 4C , S2) in ESRP1 knockdown cells, further supporting a shift towards a mesenchymal state.
Figure 4. Knockdown of ESRP1 induces EMT in H1975 cells. A) Immunofluorescence images for hybrid E/M H1975 cells -mock (leftmost column), treated with control siRNA (2 nd column from the left), and treated with two independent siRNAs targeting ESRP1 (3 rd , 4 th columns from the left). B) Western blot showing changes in ESRP1, CDH1, VIM, and ZEB1 levels. C) Bright-field microscopy images of mock (top) and si-ESRP1 #2 treated H1975 cells (bottom).
ESRP1 expression correlates with prognosis of breast cancer patients
PSFs such as GRHL2 associate with poor prognosis in breast cancer [27, 39] , motivating us to investigate the correlation of ESRP1 with patient survival rates. Higher levels of ESRP1, and a higher ratio of ESRP1/HAS2 and ESRP1/ZEB1, correlate with poor relapse-free survival (RFS) and overall survival (OS) in multiple independent breast cancer datasets ( Figure 5A-C, S3) . These results suggest that the ZEB1/ESRP1/HAS2/CD44 axis may play important functional roles in breast cancer progression.
Figure 5. Correlation of ESRP1, ESRP1/HAS2, and ESRP1/ZEB1 with patient prognosis. Kaplan-Meier curves for relapse-free survival for A) GSE 17705, B) GSE 42568, and C) GSE 1456. HR stands for Hazard Ratio, i.e. the ratio of likelihood of relapse-free survival of patients with low ESRP1 as compared with those with high ESRP1. First column is for ESRP1, middle column is for ESRP1/HAS2 ratio, and right column is for ESRP1/ZEB1 ratio. Red curve shows patients with high ESRP1 levels, green curves patients with low ESRP1 levels (separated by median).
Discussion
EMT is affected by multiple cross-wired cell-intrinsic and cell-extrinsic signals, including mechanical regulation through factors such as matrix stiffness [8, 9, 40] . Hyaluronan -also known as Hyaluronic Acid (HA) -is a proteoglycan that forms a scaffold for assembly of extracellular matrix (ECM). It mediates its metastasis-promoting effects largely by interacting with various isoforms of the cell surface receptor CD44 [41] . The relative abundance of these isoforms is regulated by an alternative splicing regulatory ESRP1 [29, 30] that is altered during EMT in multiple cancer types [26, 30] . HA-CD44 interactions can activate ZEB1 -a key transcription factor driving EMT -which, in turn, not only inhibits ESRP1, but also upregulates HAS2 that synthesizes HA [28, 29] . Put together, this set of feedback loops and complex interactions give rise to a highly nonlinear dynamic regulation of epithelial-hybrid-mesenchymal phenotypic transition that we characterized here through an integrated theoretical-experimental approach.
Our mathematical model predicts that the nonlinear dynamics emerging from these autocrine interconnected feedback loops can enable three phenotypes -epithelial (low ZEB1), mesenchymal (high ZEB1) and hybrid E/M (intermediate ZEB1). Multiple recent studies have identified a hybrid E/M phenotype at a single-cell level in cell lines, primary tumors, circulating tumor cells (CTCs) and metastatic tumors, across cancer types [42] . Cells in a hybrid E/M phenotype, in contrast to those in solely epithelial or mesenchymal states, can exhibit enhanced tumor-initiation potential, drug resistance and anoikis resistance in vitro and in vivo [43] [44] [45] [46] [47] [48] [49] . Moreover, many CTC clusters -the primary harbingers of metastasis [50] -exhibit a hybrid E/M signature [51] . These observations drive attention toward mechanisms maintaining a hybrid E/M phenotype [27, 37, [52] [53] [54] .
Our experimental observations that ESRP1 overexpression can reverse EMT in MCF10A cells treated with TGFβ for 21 days, and that ESRP1 knockdown can drive EMT in H1975 cells propose ESRP1 as a potential factor that can stabilize a hybrid E/M phenotype. This idea is strengthened by our computational analysis using RACIPE that showing an enrichment of hybrid E/M phenotype when the inhibition of ESRP1 by ZEB1 is deleted (i.e. increased ESRP1 levels effectively). Finally, similar to the prognostic ability of GRHL2 and OVOL [27, 39] -factors that can stabilize a hybrid E/M phenotype [25, 27, 37, 38] -higher levels of ESRP1 have been associated with (a) poor OS in breast cancer, (b) poor 5-year progression-free survival (PFS) and OS in epithelial ovarian cancer samples [55, 56] , and (c) poor prognosis of distant metastasis in breast cancer samples [57] . Put together, these observations support a case for ESRP1 to be referred to as 'phenotypic stability factor' (PSF). However, including ESRP1 and its interconnections with the miR-200/ZEB circuit did not change the bifurcation diagram of the circuit, as was observed for other PSFs such as GRHL2, OVOL2, and ∆NP63α [25, 27, 54] .
Higher levels of ESRP1, as well as higher ratios of ESRP1/ZEB1 and/or ESRP1/HAS2 can predict poor survival in multiple breast cancer datasets. This observation indicates that both the ZEB1-ESRP1 and ZEB1-HAS2 axes may regulate ZEB1 levels simultaneously. Besides breast cancer, ZEB1 has been shown to directly repress ESRP1 in NSCLC [58, 59] , explaining the negative correlation between them in 22 NSCLC cell lines [60] . Our results showing that ESRP1 knockdown alters ZEB1 levels in H1975 -a hybrid E/M NSCLC cell line -suggest that this mutual inhibition between ESRP1 and ZEB1 may be functionally active in NSCLC. Increased ESRP1 can enrich for CD44v, thus consistent with the prognostic ability of ESRP1, higher levels of CD44v, but not high CD44s or total CD44 levels, are prognostic markers for distant metastases in lung and breast cancer [57] .
CD44v can contribute to metastasis in multiple ways, e.g. by controlling the stability of cysteine transporter xCT that enables defense against enhanced oxidative stress [61] . Another example would be the production of an adhesive matrix -likely via anchoring to hyaluronan -to which tumor cells can attach during metastasis [62] . Contrarily, CD44s can also accelerate metastasis by increasing ZEB1 levels through HA-dependent and/or HA-independent pathways [28, 29] . Thus, a fine-tuned balance of CD44s and CD44v isoforms may provide additional metastatic advantages. This balance is likely to correspond to a hybrid E/M phenotype which, as discussed above, may be more aggressive than cells in solely epithelial or mesenchymal states. Future studies would need sophisticated experimental models to understand spatiotemporal expression and function of CD44 isoforms during cancer progression.
In conclusion, our results demonstrate how two interconnected feedback loops of ZEB1 including ESRP1, HAS2, and CD44 govern the dynamics of EMT/MET and enable the existence of a stable hybrid E/M phenotype. ZEB1 can not only enforce its own expression through these loops, but also alter its microenvironment, thus enhancing non-cell autonomous effects of EMT. Similar non-cell autonomous effects can lead to a cooperative behavior between epithelial and mesenchymal cells in establishing metastases [44, 63, 64] . Moreover, these non-cell autonomous effects of EMT mediated by ZEB1 may help offer a plausible explanation why metastasis can be blunted largely by knockout of ZEB1 [65] , but not necessarily by that of SNAIL or TWIST [66] . H1975 Cells were lysed in RIPA lysis assay buffer (Pierce) supplemented with protease and phosphatase inhibitor. The samples were separated on a 4-15% SDS-polyacrylamide gel (Biorad). After transfer to PVDF membrane, probing was carried out with primary antibodies and subsequent secondary antibodies. Primary antibodies were purchased from the following commercial sources: anti-CDH1 (1:1000; Cell Signaling Technology), anti-vimentin (1:1000; Cell Signaling Technology), anti-ESRP1 (0.4ug/ml; Sigma), anti-ZEB1 (1:200; Abcam) and anti-GAPDH (1:10,000; Abcam). Membranes were exposed using the ECL method (GE Healthcare) according to the manufacturer's instructions. For immunofluorescence, cells were fixed in 4% paraformaldehyde, permeabilized in 0.2% Triton X-100, and then stained with anti-CDH1 (1:100; Abcam), anti-vimentin (1:100; Cell Signaling Technology) and anti-ZEB1 (1:200; Abcam). The primary antibodies were then detected with Alexa congugated secondary antibodies (Life technologies). Nuclei were visualized by co-staining with DAPI.
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Transfection of plasmid DNA
Plasmid DNA transfection was done by using the FugeneHD transfection reagent (Promega, E2311) according to the manufacturer's instructions and harvested 72 h afterwards for protein analysis.
Antibodies
The following antibodies and dilutions were used for Western blotting: mouse anti-β-Actin (Sigma, A5441; 1:5,000), rabbit anti-ZEB1 (Sigma, HPA027524; 1:5,000), as well as HRP-coupled goat anti-rabbit IgG (Dianova, 111-035-003; 1:25,0000) and goat anti-mouse IgG (Dianova, 115-035-003; 1:25,000), mouse anti-ESRP1 (Abnova, Heidelberg, Germany, ab140671; 1:500)
RT-PCR
Total RNA was isolated following manufacturer's instructions using RNAeasy kit (Qiagen). cDNA was prepared using iScript gDNA clear cDNA synthesis kit (Bio-Rad). A TaqMan PCR assay was performed with a 7500 Fast Real-Time PCR System using TaqMan PCR master mix, commercially available primers, and FAM™-labeled probes for CDH1, VIM, ZEB1, ESRP1 and VIC™-labeled probes for 18S, according to the manufacturer's instructions (Life Technologies). Each sample was run in triplicate. Ct values for each gene were calculated and normalized to Ct values for 18S (ΔCt). The ΔΔCt values were then calculated by normalization to the ΔCt value for control.
Mathematical model
Section S1 contains all details of mathematical model development, analysis, and parameter estimates.
